Adamis Pharmaceuticals Corporation Employee Directory
Pharmaceutical ManufacturingCalifornia, United States11-50 Employees
Adamis Pharmaceuticals is a small to mid-sized biopharmaceutical company based in the San Diego region, focused on developing and commercializing specialty medicines for allergy, opioid overdose, respiratory and inflammatory diseases. Its approved products include SYMJEPI epinephrine injections for emergency treatment of acute allergic reactions, including anaphylaxis, and ZIMHI naloxone injections for opioid overdose. Its development program includes Tempol, which is being studied for COVID-19 in a Phase 2/3 trial. In 2023, Adamis completed a merger with DMK Pharmaceuticals, signaling a notable corporate development. The company serves healthcare providers and patients requiring emergency and overdose therapies, positioning itself within the specialty pharmaceutical sector with established injectables and an ongoing development pipeline.